We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$244M
1-Year Est. Return
80.12%
This Fund
S&P 500
This Quarter
Est. Return
+8.81%
1 Year Est. Return
+80.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$207M
AUM Growth
+$1.42M
(+0.69%)
Cap. Flow
+$4.92K
Cap. Flow
% of AUM
0%
Top 10 Holdings %
Top 10 Hldgs %
63.59%
Holding
43
New
4
Increased
7
Reduced
9
Closed
6
Top Buys
| 1 |
Cytokinetics
CYTK
|
+$13.9M |
| 2 |
Rezolute
RZLT
|
+$6.47M |
| 3 |
Delcath Systems
DCTH
|
+$5.58M |
| 4 |
CG Oncology
CGON
|
+$4.65M |
| 5 |
Myomo
MYO
|
+$3.23M |
Top Sells
| 1 |
Abeona Therapeutics
ABEO
|
+$8.6M |
| 2 |
Nuvation Bio
NUVB
|
+$4.31M |
| 3 |
UroGen Pharma
URGN
|
+$3.91M |
| 4 |
Verastem
VSTM
|
+$3.76M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$3.62M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Delcath Systems
DCTH
$446M
| $33M | 15.97% |
3,300,389
+400,000
| +14% | +$5.58M |
|
2
Fennec Pharmaceuticals
FENC
$375M
| $17M | 8.22% |
2,045,644
+262,800
| +15% | +$1.8M |
|
|
3
Cytokinetics
CYTK
$11.1B
| $13.2M | 6.4% |
+400,000
| New | +$13.9M |
|
4
Ocular Therapeutix
OCUL
$2.14B
| $11.3M | 5.47% |
1,218,700
| – | – |
|
|
5
IDEAYA Biosciences
IDYA
$3.53B
| $10.7M | 5.2% |
511,132
-188,868
| -27% | -$3.62M |
|
6
Xeris Biopharma Holdings
XERS
$1.45B
| $10.1M | 4.87% |
2,155,594
-340,392
| -14% | -$1.56M |
|
7
Viridian Therapeutics
VRDN
$2.11B
| $9.79M | 4.74% |
700,000
+105,000
| +18% | +$1.43M |
|
|
VRNA
8
DELISTED
Verona Pharma
VRNA
| $9.46M | 4.58% |
100,000
| – | – |
|
|
9
Verastem
VSTM
$471M
| $8.48M | 4.1% |
2,043,563
-600,954
| -23% | -$3.76M |
|
10
Replimune Group
REPL
$810M
| $8.36M | 4.05% |
900,000
+50,000
| +6% | +$436K |
|
11
MediWound
MDWD
$184M
| $7.88M | 3.82% |
407,061
-99,832
| -20% | -$1.88M |
|
|
12
Myomo
MYO
$42.1M
| $7.77M | 3.76% |
3,595,788
+892,127
| +33% | +$3.23M |
|
|
13
Rezolute
RZLT
$454M
| $7.77M | 3.76% |
+1,741,211
| New | +$6.47M |
|
|
14
UroGen Pharma
URGN
$1.92B
| $7.43M | 3.6% |
542,366
-407,634
| -43% | -$3.91M |
|
|
HELP
15
Cybin Inc
HELP
$400M
| $6.8M | 3.29% |
810,918
| – | – |
|
16
Savara
SVRA
$1.17B
| $6.05M | 2.93% |
2,654,944
| – | – |
|
17
InspireMD
NSPR
$33.7M
| $5.2M | 2.51% |
2,289,099
+14,109
| +0.6% | +$35.2K |
|
|
18
CG Oncology
CGON
$6.51B
| $5.02M | 2.43% |
+192,974
| New | +$4.65M |
|
|
PROF
19
Profound Medical
PROF
$255M
| $4.08M | 1.98% |
692,185
| – | – |
|
20
Pharvaris
PHVS
$2.43B
| $3.94M | 1.9% |
223,627
| – | – |
|
21
PolyPid
PYPD
$102M
| $3.44M | 1.67% |
975,462
-42,559
| -4% | -$125K |
|
|
DFTX
22
Definium Therapeutics
DFTX
$6.07B
| $2.73M | 1.32% |
420,000
| – | – |
|
|
KALV
23
DELISTED
KalVista Pharmaceuticals
KALV
| $1.78M | 0.86% |
157,725
-146,139
| -48% | -$1.79M |
|
24
Trevi Therapeutics
TRVI
$2.45B
| $1.64M | 0.79% |
300,000
-312,901
| -51% | -$1.95M |
|
|
CMPS
25
Compass Pathways
CMPS
$1.74B
| $1.35M | 0.65% |
482,651
-340,635
| -41% | -$1.28M |
|
Similar funds
AWG
BNMT
CA
BB
GIM
IAMOG
AWM
OCFG